Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 8041.

https://doi.org/10.1182/blood-2025-8041

Published: 2025

Journal Articles

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2025-4505

Published: 2025

Journal Articles

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph Franz, Dhaval Mehta, Kathleen Dorritie, Rushir Choksi, Taya Salman, Mike Gart, Lisa Kunst, Harshal Dave, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 8120.

https://doi.org/10.1182/blood-2025-8120

Published: 2025

Journal Articles

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Joseph Franz, Joseph Mikhael, Dhaval Mehta, Rushir Choksi, Taya Salman, Mike Gart, John Li, Harshal Dave, Lisa Kunst, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2025-3988

Published: 2025

Journal Articles

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Mike Gart, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2025-6317

Published: 2025

Journal Articles

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Blood (2025) 146 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2025-6286

Published: 2025

Journal Articles

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Steven Champaloux, John Li, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 6285.

https://doi.org/10.1182/blood-2025-6285

Published: 2025

Journal Articles

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

John O. Mascarenhas, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal

Blood (2024) 144 (Supplement 1): 6650.

https://doi.org/10.1182/blood-2024-210598

Published: 2024

Journal Articles

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Raajit Rampal, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 6649.

https://doi.org/10.1182/blood-2024-210274

Published: 2024

Journal Articles

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2024-210826

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only